USCOM LIMITED — Regulatory Filings 2010

Mar 17, 2010

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

USCOM publication on ICU fluid and septic shock

Thursday 18th March 2010: Uscom (ASX code: UCM) today announced the publication of a new study by Intensive Care specialists at the Wesley Hospital, in Brisbane, Queensland in the journal Anesthesia and Intensive Care confirming the usefulness of USCOM for guiding fluid in treatment of septic shock.

The study by Dave Sturgess and his colleagues demonstrated that non-invasive USCOM measures were more than twice as effective as invasive catheter measurement of blood pressure, or blood tests for detecting patients who required fluid treatment for septic shock. Septic shock is a serious and common disease with a high mortality, and it requires rapid and accurate treatment, usually led by administration of fluids.

Rob Phillips, the Executive Chairman of Uscom and Director of Clinical Science said “This is further evidence that USCOM is an important tool in critical care medicine. Fluid administration is the most common circulatory intervention by intensivists worldwide and this study shows USCOM methods to be twice as effective as current methods when used in treatment of septic shock. The Washington University School of Medicine also recently demonstrated that USCOM was twice as effective as invasive catheter based pressure measures for guiding fluid treatments and should become routine for management of fluids in general ICU patients. Fluid management has always been a problem for intensivists, and this recent work is evidence that USCOM can dramatically improve this common critical care practice.”

Reference: Sturgess DJ, Pascoe RLS, Scalia G, Venkatesh B. A comparison of transcutaneous Doppler corrected flow time, b-type natriuretic peptide and central venous pressure as predictors of fluid responsiveness in septic shock: a preliminary study. Anesth Int Care 2009;38(2):336-341

About Uscom

Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration. USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, India and Australia by Spacelabs Healthcare, while in China and SE Asia USCOM is distributed by Pacific Medical Systems and in New Zealand it is distributed by MedXus.

Uscom Contacts Rob Phillips Chief Executive Officer rob@uscom.com.au

Daniel Fah Company Secretary daniel.fah@uscom.com.au